Northern Trust Corp Buys 110,298 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Northern Trust Corp increased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 29.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 488,854 shares of the biotechnology company's stock after purchasing an additional 110,298 shares during the quarter. Northern Trust Corp owned 1.09% of United Therapeutics worth $172,487,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. World Investment Advisors LLC purchased a new stake in shares of United Therapeutics in the third quarter worth approximately $393,000. Tidal Investments LLC boosted its holdings in shares of United Therapeutics by 33.1% during the 3rd quarter. Tidal Investments LLC now owns 11,272 shares of the biotechnology company's stock worth $4,039,000 after buying an additional 2,803 shares during the period. Franklin Resources Inc. grew its position in shares of United Therapeutics by 97.7% in the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock valued at $89,532,000 after purchasing an additional 123,929 shares during the last quarter. Oddo BHF Asset Management Sas acquired a new stake in United Therapeutics in the 3rd quarter valued at approximately $1,698,000. Finally, Lord Abbett & CO. LLC grew its stake in shares of United Therapeutics by 29.7% in the third quarter. Lord Abbett & CO. LLC now owns 201,695 shares of the biotechnology company's stock worth $72,277,000 after acquiring an additional 46,170 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares in the company, valued at $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Raymond Dwek sold 4,000 shares of the business's stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the transaction, the director now owns 1,750 shares in the company, valued at $497,962.50. This represents a 69.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 75,500 shares of company stock worth $24,245,880 in the last 90 days. Corporate insiders own 11.90% of the company's stock.

United Therapeutics Trading Up 1.4 %

Shares of NASDAQ UTHR traded up $4.10 during midday trading on Monday, reaching $298.70. The company's stock had a trading volume of 295,744 shares, compared to its average volume of 442,469. The stock has a 50 day simple moving average of $301.96 and a 200-day simple moving average of $344.13. The stock has a market capitalization of $13.47 billion, a price-to-earnings ratio of 13.12, a PEG ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a fifty-two week low of $256.08 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the business earned $6.17 EPS. As a group, equities analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Wall Street Analyst Weigh In

UTHR has been the topic of several research reports. HC Wainwright restated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research note on Monday. JPMorgan Chase & Co. decreased their price target on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday. Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective for the company in a research report on Monday, April 21st. UBS Group upped their price target on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Finally, Wells Fargo & Company restated an "equal weight" rating and set a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $392.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.